Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Jung Won Shin

Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector. 
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.

Advertisement
Set Alert for Articles By Jung Won Shin

Latest From Jung Won Shin

Melior, Bukwang Seek Diabetes Edge With Novel Insulin Sensitizer

MLR-1023, a repositioned oral compound being developed for type 2 diabetes by Melior and Bukwang, is set to move into Phase IIb in the US and South Korea, and the firms are looking to its novel mechanism of action, improved tolerability and efficacy to carve a niche in a highly competitive sector.

Research & Development Diabetic Care

Deal Watch: Seattle Genetics Adds To Antibody-Drug Conjugate Portfolio

Looking to expand beyond Adcetris, Seattle Genetics pays $250m up front for Immunomedics' Phase I/II ADC for triple-negative breast cancer. Elsewhere in the ADC space, Swiss biotech Novimmune and South Korea's LegoChem are teaming up on a research collaboration.

Deals M & A

Interview: MedPacto Sees Robust Prospects For ‘Best-In-Class’ ALK5 Inhibitor

MedPacto is preparing for a critical Phase II US study with its potentially best-in-class ALK5 inhibitor, a potential rival to a Lilly molecule and that will be central to the South Korean bioventure’s long-term ambitions to become a global player.

Research & Development Cancer

Need To Redefine Recipe For Success In Korean Biotech?

In South Korea, success and failure in the bioventure sector seems to be measured differently to elsewhere, while other legal and investment hurdles remain, and some experts are now pointing to the need for change if the industry is to move on to the next phase.

South Korea Financing

2017 Preview: Give And Take Marks Mixed Japan, Korea Outlook

As much of Asia celebrates the Lunar New Year holidays, the pharma sector in Japan and South Korea is looking ahead to the Year of the Rooster with a mixture of uncertainty and hope, providing the industry with much to crow about either in support or opposition.

Japan South Korea

2017 Preview: Give And Take Marks Mixed Japan, Korea Outlook

As much of Asia celebrates the Lunar New Year holidays, the pharma sector in Japan and South Korea is looking ahead to the Year of the Rooster with a mixture of uncertainty and hope, providing the industry with much to crow about either in support or opposition.

Japan South Korea
See All
Advertisement
UsernamePublicRestriction

Register